文献速递垂体与肾上腺疾病

1mg地塞米松抑制试验中血清地塞米松浓度的临床与药理学决定因素

Clinical and pharmacological determinants of serum dexamethasone concentrations during dexamethasone suppression test.
PubMed 文献 · J Clin Endocrinol Metab · 2026-09-08

该观察性研究纳入546例接受1mg过夜地塞米松抑制试验(1-mg DST)的患者,同步测定血清皮质醇与地塞米松浓度。多变量分析显示年龄(β=0.24, p<0.001)和BMI(β=0.17, p=0.010)与地塞米松水平独立相关,而eGFR无关。地塞米松暴露不足(<4.5 nmol/L)见于3.3%患者,且常与皮质醇抑制不充分相关。

要点

  • 年龄和BMI是1-mg DST中地塞米松暴露的独立决定因素。
  • 肾功能和合并用药(PPI、他汀、CCB)在调整后影响有限。
  • 地塞米松暴露不足(<4.5 nmol/L)见于3.3%患者,与皮质醇抑制不充分相关。

核心结论

  • 年龄和BMI是1-mg DST中地塞米松暴露的主要决定因素,肾功能和药物的影响在调整后有限。
  • 测定地塞米松水平可能改善试验解读,但一旦达到 adequate 暴露,更高的地塞米松水平并不带来额外的皮质醇抑制。

研究设计与样本

  • 观察性研究,纳入546例接受1-mg DST并测定血清皮质醇和地塞米松水平的患者。
  • 分析临床变量(年龄、BMI、eGFR)和合并用药,采用多变量线性回归评估与地塞米松水平的关联,逻辑回归分析亚 optimal 暴露(<4.5 nmol/L)。

主要发现

  • 地塞米松浓度中位数为11.9 nmol/L。
  • 多变量分析中,年龄(β=0.24, p<0.001)和BMI(β=0.17, p=0.010)与较高地塞米松水平独立相关,eGFR无关。
  • 合并用药(PPI、他汀、钙通道阻滞剂)在单变量分析中与较高地塞米松水平相关,但敏感性分析后不再显著。
  • 年龄分层模型显示,<65岁患者中BMI和PPI使用与地塞米松相关,≥65岁患者中他汀和PPI为决定因素。
  • 排除轻度自主皮质醇分泌患者后,BMI和eGFR仍显著。

关键数值与推荐

  • 亚 optimal 地塞米松暴露定义为血清地塞米松浓度<4.5 nmol/L。

临床怎么用

  • 在解读1-mg DST结果时,应考虑年龄和BMI对地塞米松暴露的影响。
  • 对于地塞米松暴露不足的患者,皮质醇抑制不充分可能反映暴露不足而非高皮质醇血症,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The 1-mg overnight dexamethasone suppression test (1-mg DST) is widely used to screen for hypercortisolism, but its interpretation may be affected by variability in dexamethasone exposure due to clinical and pharmacological factors. OBJECTIVE: To evaluate determinants of serum dexamethasone levels during 1-mg DST and their impact on test interpretation. METHODS: Observational study including 546 patients undergoing 1-mg DST with measurement of serum cortisol and dexamethasone levels. Clinical variables (age, BMI, eGFR) and concomitant medications were analyzed. Associations with dexamethasone levels were assessed using multivariable linear regression; suboptimal exposure (<4.5 nmol/L) was evaluated by logistic analysis. RESULTS: Median dexamethasone concentration was 11.9 nmol/L. In multivariable analysis, age (β=0.24, p<0.001) and BMI (β=0.17, p=0.010) were independently associated with higher dexamethasone levels, whereas eGFR was not. Concomitant medications (PPIs, statins, calcium channel blockers) were associated with higher dexamethasone levels in univariable analyses, but not after sensitivity analyses. Age-stratified models showed that BMI and PPI use were associated with dexamethasone in patients <65 years, whereas statins and PPIs were determinants in those ≥65 years. BMI and eGFR remained significant after excluding patients with mild autonomous cortisol secretion. Suboptimal dexamethasone exposure occurred in 3.3% of patients and was frequently associated with inadequate cortisol suppression. CONCLUSIONS: Age and BMI emerged as determinants of dexamethasone exposure during 1-mg DST, while the impact of renal function and medications appears limited after adjustment. Measuring dexamethasone may improve test interpretation; however, once adequate dexamethasone exposure is achieved, higher dexamethasone levels are not associated with additional cortisol suppression.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tizianel I, Antonelli G, Mondin A, et al. Clinical and pharmacological determinants of serum dexamethasone concentrations during dexamethasone suppression test. J Clin Endocrinol Metab. 2026. PMID: 42708510. doi:10.1210/clinem/dgag370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。